ROCKVILLE, Md. and SHANGHAI, April 12, 2023 /PRNewswire/ -- SciNeuro Pharmaceuticals today announced that SNP318, a novel Lp-PLA2 inhibitor, is advancing into Phase 1 clinical trials in Australia, positioning it for global development. SNP318 is a small molecule, optimized for CNS penetrance, to induce broader anti-inflammatory benefits. It has potential in the treatment of major neurodegenerative diseases where protection and restoration of vascular health are important.
ROCKVILLE, Md. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce an executive leadership appointment, and update on key pipeline progress milestones.
SciNeuro Pharmaceuticals (SciNeuro), a leader in the discovery and development of innovative therapeutics for the treatment of CNS diseases, today...
SHANGHAI & ROCKVILLE, Md. & ZURICH--(BUSINESS WIRE)--SciNeuro Pharmaceuticals, a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, Mabylon and SciNeuro will work together to discover and develop human auto-antibodies against targets of mutual interest with a goal to develop differentiated biologic therapeutics to treat neurological diseases.